{"drugs":["Polymyxin B Sulfate"],"mono":{"0":{"id":"473890-s-0","title":"Generic Names","mono":"Polymyxin B Sulfate"},"1":{"id":"473890-s-1","title":"Dosing and Indications","sub":[{"id":"473890-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bacteremia:<\/b> 15,000 to 25,000 units\/kg\/day IV divided every 12 hours; maximum 25,000 units\/kg\/day<\/li><li><b>Bacteremia:<\/b> 25,000 to 30,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><li><b>Bacterial infection of eye:<\/b> Neosporin(R) solution, 1 to 2 drops into affected eye(s) every 4 hours for 7 to 10 days; dosage may be increased to 2 drops every hour in severe infections<\/li><li><b>Bacterial infection of eye:<\/b> Neosporin(R) ointment, apply to affected eye(s) every 3 to 4 hours for 7 to 10 days<\/li><li><b>Bacterial infection of eye:<\/b> injection, instill 1 to 3 drops of a 0.1% to 0.25% solution (10,000 to 25,000 units\/mL) OPHTHALMICALLY into affected eye(s) every hour; increase intervals as response indicates; MAX 25,000 units\/kg\/day<\/li><li><b>Bacterial infection of eye:<\/b> injection, inject SUBCONJUNCTIVALLY up to 100,000 units\/day; MAX 25,000 units\/kg\/day<\/li><li><b>Infection due to Pseudomonas aeruginosa:<\/b> 15,000 to 25,000 units\/kg\/day IV divided every 12 hours; maximum 25,000 units\/kg\/day<\/li><li><b>Infection due to Pseudomonas aeruginosa:<\/b> 25,000 to 30,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><li><b>Irrigation of urinary bladder; Adjunct:<\/b> 1 mL of neomycin-polymyxin B sulfate irrigation solution added to 1000 mL of NS for continuous bladder irrigation over 24 hours; if urine output greater than 2 L\/day, inflow rate adjusted to deliver 2000 mL over a 24-hour period; length of treatment is up to 10 days<\/li><li><b>Meningitis:<\/b> 50,000 units INTRATHECALLY once daily for 3 to 4 days, then 50,000 units intrathecally every other day for at least 2 weeks after cerebrospinal fluid cultures are negative and sugar content has returned to normal<\/li><li><b>Urinary tract infectious disease:<\/b> 15,000 to 25,000 units\/kg\/day IV divided every 12 hours; MAX 25,000 units\/kg\/day<\/li><li><b>Urinary tract infectious disease:<\/b> 25,000 to 30,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><\/ul>"},{"id":"473890-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Bacteremia:<\/b> (infants) up to 40,000 units\/kg\/day IV divided every 12 hours<\/li><li><b>Bacteremia:<\/b> (children) 15,000 to 25,000 units\/kg\/day IV divided every 12 hours; maximum 25,000 units\/kg\/day<\/li><li><b>Bacteremia:<\/b> (infants) up to 40,000 to 45,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><li><b>Bacteremia:<\/b> (children) 25,000 to 30,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><li><b>Bacterial infection of eye:<\/b> injection, instill 1 to 3 drops of a 0.1% to 0.25% solution (10,000 to 25,000 units\/mL) OPHTHALMICALLY into affected eye(s) every hour; increase intervals as response indicates; MAX 25,000 units\/kg\/day.<\/li><li><b>Bacterial infection of eye:<\/b> injection, inject SUBCONJUNCTIVALLY up to 100,000 units\/day; MAX 25,000 units\/kg\/day.<\/li><li><b>Infection due to Pseudomonas aeruginosa:<\/b> (infants) up to 40,000 units\/kg\/day IV divided every 12 hours<\/li><li><b>Infection due to Pseudomonas aeruginosa:<\/b> (children) 15,000 to 25,000 units\/kg\/day IV divided every 12 hours; maximum 25,000 units\/kg\/day<\/li><li><b>Infection due to Pseudomonas aeruginosa:<\/b> (infants) up to 40,000 to 45,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><li><b>Infection due to Pseudomonas aeruginosa:<\/b> (children) 25,000 to 30,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><li><b>Meningitis:<\/b> (younger than 2 years) 20,000 units INTRATHECALLY once a day for 3 to 4 days OR 25,000 units every other day; continue 25,000 units every other day dosing for at least 2 weeks after cerebrospinal fluid cultures are negative and sugar content has returned to normal<\/li><li><b>Meningitis:<\/b> (older than 2 years) 50,000 units INTRATHECALLY once daily for 3 to 4 days, then 50,000 units intrathecally every other day for at least 2 weeks after cerebrospinal fluid cultures are negative and sugar content has returned to normal<\/li><li><b>Urinary tract infectious disease:<\/b> (infants) up to 40,000 units\/kg\/day IV divided every 12 hours<\/li><li><b>Urinary tract infectious disease:<\/b> (children) 15,000 to 25,000 units\/kg\/day IV divided every 12 hours; maximum 25,000 units\/kg\/day<\/li><li><b>Urinary tract infectious disease:<\/b> (infants) up to 40,000 to 45,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><li><b>Urinary tract infectious disease:<\/b> (children) 25,000 to 30,000 units\/kg\/day IM divided every 4 to 6 hours; not routinely recommended due to pain at injection site<\/li><\/ul>"},{"id":"473890-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> based on recent pharmacokinetic studies, dose adjustments may not be necessary<\/li><li><b>renal impairment:<\/b> manufacturer labeling recommends MAX dose of 15,000 units\/kg\/day<\/li><\/ul>"},{"id":"473890-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bacteremia<\/li><li>Bacterial infection of eye<\/li><li>Infection due to Pseudomonas aeruginosa<\/li><li>Irrigation of urinary bladder; Adjunct<\/li><li>Meningitis<\/li><li>Urinary tract infectious disease<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Respiratory tract infection<br\/>"}]},"2":{"id":"473890-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intramuscular (Powder for Solution)<\/b><br\/>Polymyxin B sulfate should be given only to hospitalized patients when administered IM and\/or intrathecally. Therapy has been associated with potential neurotoxicity and nephrotoxicity. Monitor renal function during therapy and reduce dose in patients with renal impairment. Concurrent use of other neurotoxic or nephrotoxic agents should be avoided. Neuromuscular blockade and respiratory paralysis can occur following administration, especially when the drug is given soon after anesthesia and\/or muscle relaxants. The safety of this drug in pregnancy has not been established.<br\/><\/li><li><b>Intrathecal (Powder for Solution)<\/b><br\/>Polymyxin B sulfate should be given only to hospitalized patients when administered IM and\/or intrathecally. Therapy has been associated with potential neurotoxicity and nephrotoxicity. Monitor renal function during therapy and reduce dose in patients with renal impairment. Concurrent use of other neurotoxic or nephrotoxic agents should be avoided. Neuromuscular blockade and respiratory paralysis can occur following administration, especially when the drug is given soon after anesthesia and\/or muscle relaxants. The safety of this drug in pregnancy has not been established.<br\/><\/li><li><b>Intravenous (Powder for Solution)<\/b><br\/>Polymyxin B sulfate should be given only to hospitalized patients when administered IM and\/or intrathecally. Therapy has been associated with potential neurotoxicity and nephrotoxicity. Monitor renal function during therapy and reduce dose in patients with renal impairment. Concurrent use of other neurotoxic or nephrotoxic agents should be avoided. Neuromuscular blockade and respiratory paralysis can occur following administration, especially when the drug is given soon after anesthesia and\/or muscle relaxants. The safety of this drug in pregnancy has not been established.<br\/><\/li><\/ul>"},"3":{"id":"473890-s-3","title":"Contraindications\/Warnings","sub":[{"id":"473890-s-3-9","title":"Contraindications","mono":"hypersensitivity to polymyxins <br\/>"},{"id":"473890-s-3-10","title":"Precautions","mono":"<ul><li>concomitant or sequential use of curariform muscle relaxants or other neurotoxic or nephrotoxic drugs, particularly bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin, or colistin; avoid use<\/li><li>intramuscular or intrathecal administration; constant supervision required; administer only to hospitalized patients<\/li><li>nephrotoxicity, may occur; usual symptoms include azotemia, cellular casts, and albuminuria; discontinuation may be required if decreased urine output and rising BUN are observed<\/li><li>neurotoxic reactions manifested by irritability, weakness, drowsiness, ataxia, perioral paresthesia, numbness of the extremities, or blurring of vision may occur; increased risk in patients with renal impairment or nephrotoxicity<\/li><li>renal damage and nitrogen retention; dose reductions recommended<\/li><li>respiratory paralysis may occur; increased risk with administration following anesthesia or muscle relaxants; discontinuation required<\/li><li>Clostridium difficile-associated diarrhea, including mild diarrhea to fatal colitis, has been reported; may occur up to 2 months after antibiotic therapy; if suspected or confirmed, discontinuation may be required<\/li><li>superinfection may occur<\/li><\/ul>"},{"id":"473890-s-3-11","title":"Pregnancy Category","mono":"Polymyxin B: Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"473890-s-3-12","title":"Breast Feeding","mono":"Polymyxin B: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"473890-s-4","title":"Drug Interactions","sub":{"2":{"id":"473890-s-4-15","title":"Moderate","mono":"<ul><li>Alcuronium (probable)<\/li><li>Atracurium (probable)<\/li><li>Cisatracurium (probable)<\/li><li>Doxacurium (probable)<\/li><li>Fazadinium (probable)<\/li><li>Gallamine (probable)<\/li><li>Hexafluorenium (probable)<\/li><li>Metocurine (probable)<\/li><li>Mivacurium (probable)<\/li><li>Pancuronium (probable)<\/li><li>Pipecuronium (probable)<\/li><li>Rapacuronium (probable)<\/li><li>Rocuronium (probable)<\/li><li>Tubocurarine (probable)<\/li><li>Vecuronium (probable)<\/li><\/ul>"}}},"5":{"id":"473890-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Diarrhea<br\/><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea<\/li><li><b>Neurologic:<\/b>Neurotoxicity<\/li><li><b>Renal:<\/b>Nephrotoxicity<\/li><li><b>Respiratory:<\/b>Respiratory tract paralysis<\/li><\/ul>"},"6":{"id":"473890-s-6","title":"Drug Name Info","sub":{"2":{"id":"473890-s-6-19","title":"Class","mono":"Antibiotic<br\/>"},"3":{"id":"473890-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"473890-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"473890-s-7","title":"Mechanism Of Action","mono":"Polymyxin B sulfate is a basic polypeptide antibiotic that has bactericidal activity against nearly all strains of gram-negative bacilli, except those of the Proteus group. It exerts its effect by increasing bacterial cell membrane permeability leading to death of the cell. It is not effective against gram-positive bacteria, fungi, or gram-negative cocci.<br\/>"},"8":{"id":"473890-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"473890-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, IM: 2 hours (Kucers &amp; Bennett, 1987)<\/li><li>Bioavailability, Oral: 0%<\/li><\/ul>"},"1":{"id":"473890-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 78.5% to 92.4%, critically ill subjects; 55.9%, healthy subjects<\/li><li>Vd: 71 to 194 mL\/kg (critically ill subjects)<\/li><\/ul>"},"3":{"id":"473890-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 0.04% to 4.04% unchanged<\/li><li>Renal clearance: 0.00032 to 0.0039 mL\/min\/kg; 0.061 L\/hr<\/li><li>Total body clearance: 0.27 to 0.81 mL\/min\/kg; 0.0276 L\/hr\/kg<\/li><\/ul>"},"4":{"id":"473890-s-8-27","title":"Elimination Half Life","mono":"6 hours <br\/>"}}},"9":{"id":"473890-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>refrigerate parenteral products after preparation and use within 72 hours<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>not routinely recommended because of severe pain<\/li><li>dissolve 500,000 units in 2 mL of sterile water for injection, NS, or procaine hydrochloride 1% injection<\/li><\/ul><\/li><li><b>Intrathecal<\/b><br\/>dissolve 500,000 units in 10 mL of NS (final concentration 50,000 units\/mL)<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>dissolve 500,000 units in 300 to 500 mL of D5W; infuse as continuous drip<\/li><li>may be infused intermittently every 12 hours; infusion durations of 60 to 120 minutes have been well-tolerated in adults<\/li><\/ul><\/li><li><b>Ophthalmic<\/b><br\/>dissolve 500,000 units in 20 to 50 mL of sterile water for injection or NS (final concentration 10,000 to 25,000 units\/mL or 0.1% to 0.25%)<br\/><\/li><\/ul>"},"10":{"id":"473890-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement or reduction in fever may indicate efficacy<\/li><li>CBC normalization may indicate efficacy<\/li><li>(injection) renal function; baseline and frequently during parenteral therapy<\/li><li>(injection) blood levels of the drug; baseline and frequently during parenteral therapy<\/li><\/ul>"},"11":{"id":"473890-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Injection Powder for Solution: 500000 U<br\/><\/li><li><b>Novaplus Polymyxin B Sulfate<\/b><br\/>Injection Powder for Solution: 500000 U<br\/><\/li><\/ul>"},"13":{"id":"473890-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report signs\/symptoms of nephrotoxicity.<\/li><li>Patient should report signs\/symptoms of neurotoxicity, especially when given soon after anesthesia or muscle relaxants.<\/li><li>Instruct patient on proper instillation technique.<\/li><li>Patients using ophthalmic preparation should not use any other eye drops or medications unless approved by healthcare professional.<\/li><\/ul>"}}}